December 2025 Clinical Update
December 2025 Clinical Update January 12, 2026 Jake Goll, PharmD (jake.goll@theprismhealthgroup.com) serves as the clinical consultant at Prism Health Group, where he provides end-to-end oversight of clinical strategy through in-depth data analysis, proactive consultation, and subject matter expertise. He supports client and broker engagements, develops tailored insights using pharmacy claims data, and delivers […]
November 2025 Clinical Update
November 2025 Clinical Update Jake Goll, PharmD (jake.goll@theprismhealthgroup.com) serves as the clinical consultant at Prism Health Group, where he provides end-to-end oversight of clinical strategy through in-depth data analysis, proactive consultation, and subject matter expertise. The Rapidly Evolving Economics of GLP-1s and Biosimilars In a marketplace where brand drug pricing tends to follow a […]
October 2025 Clinical Recap
October 2025 Clinical Recap Jake Goll, PharmD (jake.goll@theprismhealthgroup.com) serves as the clinical consultant at Prism Health Group, where he provides end-to-end oversight of clinical strategy through in-depth data analysis, proactive consultation, and subject matter expertise. GLP-1 Class Update: Rybelsus Gains Cardiovascular Indication Another GLP-1 has expanded its label. On October 17, 2025, Novo Nordisk […]
September 2025 Clinical Recap
September 2025 Clinical Recap October 3, 2025 Jake Goll, PharmD (jake.goll@theprismhealthgroup.com) serves as the clinical consultant at Prism Health Group, where he provides end-to-end oversight of clinical strategy through in-depth data analysis, proactive consultation, and subject matter expertise. September Policy Shake-Up: MFN and Tariffs September was anything but quiet in Washington when it comes to […]
August 2025 Clinical Recap
August 2025 Clinical Recap September 3, 2025 Jake Goll, PharmD (jake.goll@theprismhealthgroup.com) serves as the clinical consultant at Prism Health Group, where he provides end-to-end oversight of clinical strategy through in-depth data analysis, proactive consultation, and subject matter expertise. Repatha’s Expanding Role: Managing Cost and Access Last month, the FDA expanded Repatha’s label to include […]
July 2025 Clinical Recap
July 2025 Clinical Recap August 4, 2025 Jake Goll, PharmD (jake.goll@theprismhealthgroup.com) serves as the clinical consultant at Prism Health Group, where he provides end-to-end oversight of clinical strategy through in-depth data analysis, proactive consultation, and subject matter expertise. AbbVie Biologic Portfolio Review and Biosimilar Persistence Somehow, we’ve already passed the halfway mark of 2025 […]
June 2025 Clinical Recap
June 2025 Clinical Recap July 2, 2025 Jake Goll, PharmD (jake.goll@theprismhealthgroup.com) serves as the clinical consultant at Prism Health Group, where he provides end-to-end oversight of clinical strategy through in-depth data analysis, proactive consultation, and subject matter expertise. Weight Regain After GLP-1 Discontinuation One of the more frequently discussed challenges in the management […]
May 2025 Clinical Recap
May 2025 Clinical Recap June 3, 2025 Jake Goll, PharmD (jake.goll@theprismhealthgroup.com) serves as the clinical consultant at Prism Health Group, where he provides end-to-end oversight of clinical strategy through in-depth data analysis, proactive consultation, and subject matter expertise. Wegovy vs Zepbound: Navigating New Study Results and Updated PBM Strategies May marked an eventful month […]
April 2025 Clinical Recap
April 2025 Clinical Recap May 5, 2025 Jake Goll, PharmD (jake.goll@theprismhealthgroup.com) serves as the clinical consultant at Prism Health Group, where he provides end-to-end oversight of clinical strategy through in-depth data analysis, proactive consultation, and subject matter expertise. Gene Therapy: Big Talk, Slow Uptake Gene Therapy: Big Talk, Slow Uptake Gene […]
March 2025 Clinical Recap
April 2025 Clinical Recap May 5, 2025 Jake Goll, PharmD (jake.goll@theprismhealthgroup.com) serves as the clinical consultant at Prism Health Group, where he provides end-to-end oversight of clinical strategy through in-depth data analysis, proactive consultation, and subject matter expertise. Gene Therapy: Big Talk, Slow Uptake Novo Nordisk Enters the GLP-1 Direct-to-Consumer Space […]